Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally.
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has Heska's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HSKN's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: HSKN exceeded the German Medical Equipment industry which returned 23.5% over the past year.
Return vs Market: HSKN exceeded the German Market which returned 10.3% over the past year.
Price Volatility Vs. Market
How volatile is Heska's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Heska undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: HSKN (€87) is trading above our estimate of fair value (€82.22)
Significantly Below Fair Value: HSKN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: HSKN is unprofitable, so we can't compare its PE Ratio to the DE Medical Equipment industry average.
PE vs Market: HSKN is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HSKN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HSKN is good value based on its PB Ratio (3.6x) compared to the DE Medical Equipment industry average (4.9x).
How is Heska forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HSKN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: HSKN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HSKN's is expected to become profitable in the next 3 years.
Revenue vs Market: HSKN's revenue (16.5% per year) is forecast to grow faster than the German market (5.9% per year).
High Growth Revenue: HSKN's revenue (16.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HSKN's Return on Equity is forecast to be low in 3 years time (4.5%).
How has Heska performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HSKN is currently unprofitable.
Growing Profit Margin: HSKN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HSKN is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.
Accelerating Growth: Unable to compare HSKN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HSKN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-14.2%).
Return on Equity
High ROE: HSKN has a negative Return on Equity (-5.23%), as it is currently unprofitable.
How is Heska's financial position?
Financial Position Analysis
Short Term Liabilities: HSKN's short term assets ($158.4M) exceed its short term liabilities ($32.9M).
Long Term Liabilities: HSKN's short term assets ($158.4M) exceed its long term liabilities ($74.1M).
Debt to Equity History and Analysis
Debt Level: HSKN's debt to equity ratio (18.5%) is considered satisfactory.
Reducing Debt: HSKN's debt to equity ratio has increased from 3.3% to 18.5% over the past 5 years.
Debt Coverage: HSKN's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if HSKN's interest payments on its debt are well covered by EBIT.
What is Heska current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HSKN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HSKN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HSKN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HSKN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: HSKN is not paying a notable dividend for the German market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HSKN's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Wilson (48 yo)
Mr. Kevin S. Wilson has been President of Heska Corporation since February 24, 2013. Mr. Wilson has been Chief Executive Officer of Heska Corporation since March 31, 2014. He served as Chief Operating Offi ...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD609.30K) is below average for companies of similar size in the German market ($USD1.30M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
|CEO, President & Director||6.42yrs||US$609.30k||2.5% |
|Executive VP & CFO||1.25yrs||US$1.47m||0.040% |
|Executive VP & COO||1yr||US$311.22k||0.53% |
|Chief Commercial Officer||0.33yr||US$310.34k||0.14% |
|Executive VP||0.33yr||no data||0.00015% |
|Director of Investor Relations||no data||no data||no data|
|Executive Vice President of International Diagnostics||2.33yrs||US$3.56m||0.27% |
|VP of Imaging Operations||no data||no data||no data|
|VP, General Counsel & Secretary||no data||no data||0.0020% |
|Vice President of Heska Des Moines||no data||no data||no data|
Experienced Management: HSKN's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
|CEO, President & Director||6.42yrs||US$609.30k||2.5% |
|Independent Director||1.42yrs||US$108.80k||0.031% |
|Independent Chairman of the Board||1.83yrs||US$134.48k||0.054% |
|Independent Director||9.08yrs||US$121.98k||0.073% |
|Independent Director||6.75yrs||US$113.48k||0.35% |
|Independent Director||5.58yrs||US$125.98k||0.044% |
Experienced Board: HSKN's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HSKN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.1%.
Heska Corporation's company bio, employee growth, exchange listings and data sources
- Name: Heska Corporation
- Ticker: HSKN
- Exchange: DB
- Founded: 1988
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$968.170m
- Listing Market Cap: US$821.008m
- Shares outstanding: 9.44m
- Website: https://www.heska.com
Number of Employees
- Heska Corporation
- 3760 Rocky Mountain Avenue
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HSKA||NasdaqCM (Nasdaq Capital Market)||Yes||Public Common Stock||US||USD||Jul 1997|
|HSKN||DB (Deutsche Boerse AG)||Yes||Public Common Stock||DE||EUR||Jul 1997|
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The compa ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/12 21:19|
|End of Day Share Price||2020/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.